Priorities
Focused Growth and Innovation
01
Incumbent Manufacturing
We aim to retain and grow existing firms and U.S. manufacturing, driving investment into disadvantaged Greater Phoenix areas and partnering with SelectUSA and similar programs for job creation and global market insights.
Our strategy focuses on identifying key technologies to boost productivity, understanding manufacturing needs to strengthen supply chain resilience and prioritizing new technology acquisition to keep firms at the forefront of innovation and competitive growth.
02
Workforce Development
We are addressing the challenges of meeting industry demand, including changing skill needs for medical device manufacturing, with an additional focus on K-12 pipeline strategies to develop talent in underserved communities.
We are dedicated to attracting talent in medical device (MD) manufacturing, highlighting the sector's opportunities and benefits. We are establishing clear career pathways that offer progression and growth within the industry, ensuring individuals can see a long-term future and development in their roles.
03
Lab-to-Market
We are advancing medical device commercialization with improved IP and licensing policies, enhanced clinical trial collaborations and stronger supply chain resiliency.
Our strategy includes accelerating industry partnerships to foster innovation and quicker market entry for new products. We are focusing on shared resource access and fast prototyping to streamline development and respond swiftly to market needs, thereby expediting the pace of medical device development.
04
Venture Capital Development
We are developing strategies to support growth for existing startups, providing entrepreneurship resources for new startups and increasing access to capital.
To enhance this initiative, we are fostering innovation in medical device manufacturing, allowing companies to fail faster and learn, thereby speeding up development. We are developing sophisticated capital solutions and collaborating with tech transfer and corporate venture capital, facilitating quicker transitions from research to market-ready products.
